Next Article in Journal
A Developmental Perspective on Paragangliar Tumorigenesis
Next Article in Special Issue
Role of Notch Signaling Pathway in Glioblastoma Pathogenesis
Previous Article in Journal
Brain Metastases from Lung Cancer: Is MET an Actionable Target?
Previous Article in Special Issue
Protein Phosphatases—A Touchy Enemy in the Battle Against Glioblastomas: A Review
Open AccessReview

Targeting the Post-Irradiation Tumor Microenvironment in Glioblastoma via Inhibition of CXCL12

Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany
Division of Clinical Neurooncology, Department of Neurology and West German Cancer Center (WTZ), University Hospital Essen and German Cancer Consortium, Partner Site University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany
Division of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Center, 53105 Bonn, Germany
CEO, University Medical Center Freiburg, 79110 Freiburg, Germany
Skin Cancer Unit, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, 68167 Mannheim, Germany
Department of Neurology, Stanford University School of Medicine, Stanford, CA 94305, USA
Author to whom correspondence should be addressed.
Cancers 2019, 11(3), 272;
Received: 7 January 2019 / Revised: 14 February 2019 / Accepted: 20 February 2019 / Published: 26 February 2019
(This article belongs to the Special Issue Glioblastoma: State of the Art and Future Perspectives)
Radiotherapy is a mainstay in glioblastoma therapy as it not only directly targets tumor cells but also depletes the tumor microvasculature. The resulting intra-tumoral hypoxia initiates a chain of events that ultimately leads to re-vascularization, immunosuppression and, ultimately, tumor-regrowth. The key component of this cascade is overexpression of the CXC-motive chemokine ligand 12 (CXCL12), formerly known as stromal-cell derived factor 1 (SDF-1). We here review the role of CXCL12 in recruitment of pro-vasculogenic and immunosuppressive cells and give an overview on future and current drugs that target this axis. View Full-Text
Keywords: glioblastoma; radiotherapy; CXCL12 glioblastoma; radiotherapy; CXCL12
Show Figures

Figure 1

MDPI and ACS Style

Giordano, F.A.; Link, B.; Glas, M.; Herrlinger, U.; Wenz, F.; Umansky, V.; Brown, J.M.; Herskind, C. Targeting the Post-Irradiation Tumor Microenvironment in Glioblastoma via Inhibition of CXCL12. Cancers 2019, 11, 272.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop